935 studies found for:    ESR1
Show Display Options
Rank Status Study
1 Recruiting Validation of [18F]FES for Imaging of Brain Estrogen Receptors
Conditions: Psychiatric/Mood Disorder / Patient;   Estrogen Receptor Levels;   Premenopausal;   Postmenopausal
Intervention: Procedure: FES-PET
2 Active, not recruiting An Open Label Study of Postmenopausal Women With Oestrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Treated With Everolimus (RAD001) With Exemestane, With Exploratory Epigenetic Marker Analysis
Condition: Oestrogen Receptor Positive Advanced Breast Cancer
Interventions: Drug: RAD001;   Drug: Exemestane
3 Completed
Has Results
A Study of the Effect of Estrogen on Estrogen Receptor Biomarkers in Healthy Postmenopausal Women (0000-094)(COMPLETED)
Condition: Postmenopause
Interventions: Drug: Comparator: placebo;   Drug: Comparator: Estrace
4 Active, not recruiting Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
Conditions: Estrogen Receptor Positive Tumor;   Breast Cancer
Intervention: Drug: E7389 (eribulin mesylate) and capecitabine
5 Recruiting BKM120 and Fulvestrant for Treating Postmenopausal Patients With Estrogen Receptor-Positive Stage IV Breast Cancer
Conditions: Estrogen Receptor-positive Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: BKM120;   Drug: Fulvestrant;   Procedure: biopsy
6 Recruiting Fluorestradiol (FES) PET/CT for Imaging Estrogen Receptor Status
Condition: Breast Cancer
Interventions: Drug: Fluorestradiol (FES);   Procedure: PET/CT Imaging
7 Recruiting Broccoli Sprout Extract in Treating Patients With Estrogen Receptor-Positive Breast Cancer
Conditions: Estrogen Receptor-positive Breast Cancer;   Invasive Ductal Breast Carcinoma;   Invasive Lobular Breast Carcinoma;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage II Breast Cancer
Interventions: Drug: broccoli sprout extract;   Other: placebo;   Other: laboratory biomarker analysis
8 Recruiting Tamoxifen Citrate in Treating Premenopausal Women With Estrogen Receptor-Positive Breast Cancer
Conditions: Estrogen Receptor-positive Breast Cancer;   Stage I Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: tamoxifen citrate;   Genetic: polymerase chain reaction;   Other: pharmacological study;   Genetic: gene expression analysis;   Other: immunohistochemistry staining method;   Other: pharmacogenomic studies;   Other: matrix-assisted laser desorption/ionization time of flight mass spectrometry;   Genetic: polymorphism analysis;   Procedure: therapeutic conventional surgery;   Genetic: nucleic acid sequencing;   Genetic: protein analysis
9 Not yet recruiting Adjuvant Endocrine Therapy for Estrogen Receptor-beta Positive Triple Negative Breast Cancer
Condition: Female Breast Cancer
Intervention: Drug: Toremifene; Anastrozole
10 Recruiting Ruxolitinib in Estrogen Receptor Positive Breast Cancer
Condition: Estrogen-receptor Positive Invasive Metastatic Breast Cancer
Intervention: Drug: Ruxolitinib
11 Terminated Goserelin and Letrozole or Anastrozole in Premenopausal Patients With Stage II-III Estrogen Receptor-Positive Breast Cancer
Conditions: Estrogen Receptor-positive Breast Cancer;   HER2-negative Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Drug: goserelin acetate;   Drug: letrozole;   Drug: anastrozole;   Drug: chemotherapy;   Procedure: Surgery
12 Completed Fulvestrant (FASLODEX™) as a Treatment in Postmenopausal Women With Estrogen Receptor Positive Breast Cancer
Condition: Breast Cancer
Intervention: Drug: Fulvestrant
13 Completed Epidemiology Study in Postmenopausal Women With Estrogen Receptor Positive Breast Cancer
Condition: Hormon Receptor Positive Breast Cancer
Intervention:
14 Active, not recruiting
Has Results
Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
Condition: Breast Cancer
Interventions: Drug: Everolimus;   Drug: Placebo;   Drug: Exemestane
15 Recruiting Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery
Conditions: Estrogen Receptor-positive Breast Cancer;   HER2-negative Breast Cancer;   Invasive Ductal Breast Carcinoma;   Invasive Lobular Breast Carcinoma;   Recurrent Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Drug: fulvestrant;   Drug: anastrozole
16 Recruiting Selective Estrogen Receptor Modulators - A Potential Treatment for Psychotic Symptoms of Schizophrenia
Conditions: Schizophrenia;   Schizoaffective Disorder;   Schizophreniform Disorder
Interventions: Drug: Raloxifene hydrochloride;   Other: Lactose Capsules
17 Recruiting Selective Estrogen Receptor Modulators (SERMs) - A Potential Treatment for Psychotic Symptoms of Schizophrenia in Men?
Conditions: Schizophrenia;   Schizoaffective Disorder;   Schizophreniform Disorder
Interventions: Drug: Raloxifene Hydrochloride;   Drug: Placebo
18 Completed The Use of Selective Estrogen Receptor Modulators in the Treatment of Schizophrenia- a Pilot Study
Conditions: Schizophrenia;   Schizoaffective Disorder;   Schizophreniform Disorder
Interventions: Drug: Raloxifene;   Drug: Estradiol/dyhydroprogestrone
19 Recruiting Gene-polymorphisms Relating to Human Subfertility
Conditions: Estradiol Receptor Polymorphism;   Progesterone Receptor Polymorphism;   IVF;   Subfertility
Intervention:
20 Active, not recruiting
Has Results
Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.
Condition: Breast Cancer
Intervention: Drug: Fulvestrant

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years